Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-09-05
2010-11-30
Fetterolf, Brandon J (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S155000
Reexamination Certificate
active
07842681
ABSTRACT:
Methods of reducing the number of platelets in mammals and preventing or treating pro-thrombotic conditions and diseases that are characterized by an excess of, or undesired activation of, platelets using inhibitors of anti-apoptotic Bcl-2 family protein members is disclosed.
REFERENCES:
patent: 5306709 (1994-04-01), Gewirtz
patent: 6703382 (2004-03-01), Wang et al.
patent: 6720338 (2004-04-01), Augeri et al.
patent: 7030115 (2006-04-01), Elmore et al.
patent: 7358251 (2008-04-01), Elmore et al.
patent: 7390799 (2008-06-01), Bruncko et al.
patent: 7449485 (2008-11-01), Elmore et al.
patent: 7504512 (2009-03-01), Augeri et al.
patent: 7585858 (2009-09-01), Elmore et al.
patent: 7642260 (2010-01-01), Bruncko et al.
patent: 2002/0086887 (2002-07-01), Augeri et al.
patent: 2003/0119894 (2003-06-01), Murthy et al.
patent: 2004/0209907 (2004-10-01), Franklin
patent: 2006/0128706 (2006-06-01), Bruncko et al.
patent: 2006/0258657 (2006-11-01), Bruncko et al.
patent: 2007/0015787 (2007-01-01), Bruncko et al.
patent: 2007/0027135 (2007-02-01), Bruncko et al.
patent: 2007/0072860 (2007-03-01), Bruncko et al.
patent: 2008/0287419 (2008-11-01), Bruncko et al.
patent: 230136 (1991-12-01), None
patent: WO 00/04901 (2000-02-01), None
patent: WO 02/13833 (2002-02-01), None
patent: WO 02/24636 (2002-03-01), None
patent: WO 02/098848 (2002-12-01), None
patent: WO 2005/049594 (2005-06-01), None
patent: WO 2007/040650 (2007-04-01), None
patent: WO 2008/017121 (2008-02-01), None
patent: WO 2008/017123 (2008-02-01), None
Hawkins et. al., Meyloproliferative Disorders, University of Maryland Medical Center, online publication, Oct. 19, 2006.
Oltersdorf., An inhibitor of Bcl-2 family proteins induces regression of solid tumours, Nature, vol. 435, May 15, 2005.
Zhang et. al. (Haematologica (2004) 89:1199-1206).
Gangat et. al. (Expert Opinion on Pharmacotherapy (2008) 9:1679-1685.
Lengfelder et. al. (Seminars in Thrombosis and Hemostasis (2006) 32:267-275).
Yanhong Ma et. al., Biochimmica et Biophysica Acta (2009) 1073-1079.
Finazzi, et al., “Essential Thrombocythemia”, Seminars in Hematology, 42, 230-238 (2005).
Harrison, et al., “Hydroxyurea Compared with Anagrelide in high-Risk Essential Thrombocythemia”, New Engl J Med, 353, 33-45 (2005).
IUPAC 1974 Recommendations for Sec E, Fundamental Stereochemistry, Pure Appl Chem,45,13-30 (1976).
Lengfelder, et al., “Diagnosis and Therapy of Polycythemia Vera”, Seminars In Thrombosis and Hemostasis, 32 (3), 267-275 (2006).
Mitra, et al., “In Stent restenosis: bane of the stent era”, J Clin Pathol, 59, 232-239 (2006).
Petros, et al., “Solution structure of the antiapoptotic protein bcl-2”, PNAS, 98(6), 3012-3017 (2001).
Sattler, et al., “Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis”, Science 275, 983-986 (1997).
Weston, et al., “Antiplatelet Drugs in Cardiovascular Diseases”, International Journal of Clinical Practice, 57(10), 898-905 (2003).
Zhang, et al., “Development of a high-throughput fluorescence polarization assay for Bcl-xL”, Analytical Biochemistry, 307, 70-75 (2002).
Zhang, et al., “Bcl-2 family proteins are essential for platelet survival”, Cell death and Differentiation, 14, 943-951 (2007).
Mason, et al., “The Bcl-2 Protein Family Is Essential for Platelet Survival in Vivo”, Blood (48th ASH Annual Meeting Abstracts) vol. 108 No. 11, Part 1 pp. 209A (2006).
Merritt, et al., “The Efficacy and Safety of Perioperative Antiplatelet Therapy”, Journal of Thrombosis and Thrombolysis, 17(1), 21-27 (2004).
Letai, A., 2005, “The BCL-2 network: Mechanistic insights and therapeutic potential,”Drug Discovery Today: Disease Mechanisms, vol. 2(2):145-151.
Mitten, M.J. et al., 2005, “The Bcl-2 inhibitor ABT-737 shows significant anit-tumor efficacy in a model of non-Hodgkin's B cell lymphoma,”Proceedings of the Annual Meeting of the American Association for Cancer Research, vol. 46:399-400.
PCT International Written Opinion dated Jul. 29, 2008, in International Application No. PCT/US2007/077579, filed Sep. 5, 2007.
PCT International Search Report Jul. 29, 2008, in International Application No. PCT/US2007/077579, filed Sep. 5, 2007.
U.S.P.T.O. Non-Final Office Action dated Sep. 12, 2008, in U.S. Appl. No. 11/202,827, filed Aug. 12, 2005.
U.S.P.T.O. Non-Final Office Action dated Aug. 21, 2008, in U.S. Appl. No. 11/127,940, filed May 12, 2005.
Shimazaki, et al., “Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes”, British J Haematology, 110(3), 584-590 (2000).
Tse et al., “ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor,” May 1, 2008, Cancer Research 68(9):3421-3428.
U.S.P.T.O., Non-final Office Action dated Aug. 21, 2009 in U.S. Appl. No. 11/127,940.
Wagner et al., “Conditional deletion of theBcl-xgene from erythroid cells results in hemolytic anemia and profound splenomegaly,” Development, 127, 4949-4958 (2000).
Birgegard, et al., “Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders,” Haematologica, 2004, 89, pp. 520-527.
Degterev, et al., “Identification of small-molecule inhibitors of interaction between the BH3 domain and Bel-xL,” Nature Cell Biology, 2001. 3, pp. 173-182.
Enyedy, et al., “Discovery of Small-Molecule Inhibitors of Bcl-2 through Structure-Based Computer Screening,” J. Med. Chem., 2001, 44, pp. 4313-4324.
James, et al., “A unique clonal JAK2 mutation leading to constituative signaling causes polycythaemia vera,” Nature, 2005, 434, pp. 1144-1148.
James, et al., “A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects,” Trends in Molecular Medicine, 2005, 11, pp. 546-554.
Kutzki, et al., “Development of Potent Bcl-xl Antagonist Based on α-Helix Mimicry,” J. Am. Chem. Soc., 2002, 124, pp. 11838-11839.
Ma, et al., “Real-time bioluminescence imaging of polycythemia vera development in mice,” Biochemica et Biophysica Acta, 2009, 1792, pp. 1073-1079.
Pereira, et al., “Platelet aging in vivo is associated with activation of apoptotic pathways: studies in a model of suppressed thrombopoiesis in dogs,” Thromb. Haemost., 2002, 87(5), pp. 905-909.
P/S/L Consulting Group Inc., Press Release: “FDA Clears Agrylin for a Broader Patient Population,” Dec. 21, 1998, retrieved May 10, 2010, from Doctor's Guide: Global Edition website (http://www.pslgroup.com/dg/D57EE.htm).
Shire US Manufacturing Inc., Agrylin®—anagrelide hydrochloride capsule product label, 2005, pp. 1-8, downloaded May 16, 2010 from http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=14398#nlm34067-9.
Silva, et al., “Expression of Bcl-x in Erythroid Precursors from Patients with Polycythemia Vera,” The New England Journal of Medicine, 1998, 338, pp. 564-571.
The Leukemia & Lymphoma Society, “Polycythemia Vera,” Fact Sheet No. 13, p. 3, downloaded on May 18, 2010 from http://www.leukemia-lymphoma.org/attachments/National/br—1178803767.pdf.
Zeuner, et al., “Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells,” Blood, 2009, 113, No. 7, pp. 1522-1525.
Elmore Steven W.
Gordon Gary
Rosenberg Saul
Abbott Laboratories
Donner Gregory B.
Fetterolf Brandon J
Manzari Oona A.
Sznaidman Marcos
LandOfFree
Treatment of myeoproliferative diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of myeoproliferative diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of myeoproliferative diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4193125